Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Cirrhosis

  Free Subscription

Articles published in J Gastroenterol Hepatol

Retrieve available abstracts of 67 articles:
HTML format

Single Articles

    August 2022
  1. HA Y, Chon YE, Kim MN, Lee JH, et al
    Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:1624-1632.
    PubMed     Abstract available

  2. KIM HJ, Park SJ, Park HK, Byun DW, et al
    Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study.
    J Gastroenterol Hepatol. 2022;37:1617-1623.
    PubMed     Abstract available

    July 2022
  3. LEE H, Kim BK
    Real-world clinical features, healthcare utilization, and economic burden in decompensated cirrhosis patients; a national database.
    J Gastroenterol Hepatol. 2022 Jul 21. doi: 10.1111/jgh.15962.
    PubMed     Abstract available

  4. GIRI S, Agarwal D, Afzalpurkar S
    GGT dynamic for advanced fibrosis in NAFLD: Novel but not convincing.
    J Gastroenterol Hepatol. 2022;37:1406.

    June 2022
  5. WONG YJ, Li J, Liu C, Chen Z, et al
    CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
    J Gastroenterol Hepatol. 2022;37:1043-1051.
    PubMed     Abstract available

    May 2022
  6. DUNN W, Song X, Koestler D, Grdinovac K, et al
    Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
    J Gastroenterol Hepatol. 2022 May 25. doi: 10.1111/jgh.15900.
    PubMed     Abstract available

    March 2022
  7. HUSSAIN I, Wong YJ, Lohan R, Lin S, et al
    Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials.
    J Gastroenterol Hepatol. 2022;37:455-463.
    PubMed     Abstract available

    February 2022
  8. MUNDADA K, Goel A, Paliwal VK, Singh TP, et al
    Short course of low-dose pregabalin is effective for the treatment of restless leg syndrome in patients with cirrhosis: A pilot study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15803.
    PubMed     Abstract available

    January 2022
  9. MOLLER S, Henriksen JH, Sjostedt S, Bendtsen F, et al
    Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
    J Gastroenterol Hepatol. 2022 Jan 11. doi: 10.1111/jgh.15778.
    PubMed     Abstract available

    December 2021
  10. SATO Y, Yoneda A, Shimizu F, Nishimura M, et al
    Resolution of fibrosis by siRNA HSP47 in vitamin A-coupled liposomes induces regeneration of chronically injured livers.
    J Gastroenterol Hepatol. 2021;36:3418-3428.
    PubMed     Abstract available

    November 2021
  11. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.

  12. KUCHAY MS, Choudhary NS, Gagneja S, Mathew A, et al
    Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3204-3211.
    PubMed     Abstract available

    October 2021
  13. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
    J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
    PubMed     Abstract available

  14. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    PubMed     Abstract available

  15. TAMAKI N, Kurosaki M, Takahashi Y, Itakura Y, et al
    Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
    J Gastroenterol Hepatol. 2021;36:2960-2966.
    PubMed     Abstract available

    September 2021
  16. LI R, Ong Q, Wong CC, Chu ES, et al
    O-GlcNAcylation inhibits hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
    PubMed     Abstract available

  17. KONG F, Wen X, Wen X, Wang X, et al
    Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.
    J Gastroenterol Hepatol. 2021;36:2375-2382.
    PubMed     Abstract available

    August 2021
  18. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.

  19. CHEN H, Johnston A, Palmer A, Mickenbecker M, et al
    Too little, too late: Palliation and end-stage liver disease.
    J Gastroenterol Hepatol. 2021;36:2303-2306.
    PubMed     Abstract available

  20. MAHER S, Dowdell L, Zhang L, Zekry A, et al
    Community screening identifies undiagnosed chronic liver disease in high-risk populations.
    J Gastroenterol Hepatol. 2021;36:2255-2260.
    PubMed     Abstract available

    July 2021
  21. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available

  22. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    PubMed     Abstract available

  23. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.

  24. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available

  25. KANG HT, Jang K, Jun DW, Yoon EL, et al
    Macro-encapsulation of mesenchymal stem cells in acute and chronic liver injury animal models.
    J Gastroenterol Hepatol. 2021;36:1997-2007.
    PubMed     Abstract available

  26. ZAREBSKA-MICHALUK D, Jaroszewicz J, Pabjan P, Lapinski TW, et al
    Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    J Gastroenterol Hepatol. 2021;36:1944-1952.
    PubMed     Abstract available

    June 2021
  27. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available

  28. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed     Abstract available

  29. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed     Abstract available

  30. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed     Abstract available

  31. YIP TC, Wong VW, Wong GL
    Liver-heart connection in diabetes mellitus.
    J Gastroenterol Hepatol. 2021;36:1385-1386.

    May 2021
  32. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    PubMed     Abstract available

  33. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    PubMed     Abstract available

  34. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    PubMed     Abstract available

  35. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available

  36. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available

    March 2021
  37. IWAKI M, Kessoku T, Ozaki A, Kasai Y, et al
    Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Mar 11. doi: 10.1111/jgh.15487.
    PubMed     Abstract available

  38. SHARMA C, Cococcia S, Ellis N, Parkes J, et al
    Systematic review: Accuracy of The Enhanced Liver Fibrosis Test for diagnosing advanced liver fibrosis and cirrhosis.
    J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482.
    PubMed     Abstract available

  39. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    PubMed     Abstract available

    February 2021
  40. WEST J, Gow PJ, Testro A, Chapman B, et al
    Exercise physiology in cirrhosis and the potential benefits of exercise interventions - a review.
    J Gastroenterol Hepatol. 2021 Feb 27. doi: 10.1111/jgh.15474.
    PubMed     Abstract available

  41. HEO YJ, Choi SE, Lee N, Jeon JY, et al
    Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
    J Gastroenterol Hepatol. 2021 Feb 18. doi: 10.1111/jgh.15465.
    PubMed     Abstract available

  42. KIM JH, Park SW, Jung JH, Park DH, et al
    Bedside Risk-Scoring Model for Predicting 6-Week Mortality in Cirrhotic Patients Undergoing Endoscopic Band Ligation for Acute Variceal Bleeding.
    J Gastroenterol Hepatol. 2021 Feb 4. doi: 10.1111/jgh.15426.
    PubMed     Abstract available

    January 2021
  43. YOSHINO K, Taura K, Iwaisako K, Masano Y, et al
    A novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy.
    J Gastroenterol Hepatol. 2021 Jan 15. doi: 10.1111/jgh.15406.
    PubMed     Abstract available

  44. YI F, Guo X, Wang L, Xu X, et al
    Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume.
    J Gastroenterol Hepatol. 2021 Jan 3. doi: 10.1111/jgh.15386.
    PubMed     Abstract available

  45. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    PubMed     Abstract available

  46. TAKEMURA K, Takizawa E, Tamori A, Nakamae M, et al
    Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
    J Gastroenterol Hepatol. 2021;36:217-224.
    PubMed     Abstract available

    December 2020
  47. TERRA C, Perez R
    Albumin for cirrhotic patients with infections unrelated to spontaneous bacterial peritonitis: A still no answered question.
    J Gastroenterol Hepatol. 2020;35:2290-2291.

    September 2020
  48. KOGISO T, Hashimoto E
    Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:1459-1460.

  49. CHEN TP, Lai M, Lin WY, Huang KC, et al
    Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.
    J Gastroenterol Hepatol. 2020;35:1636-1643.
    PubMed     Abstract available

  50. YIP TC, Lee HW, Wong VW, Wong GL, et al
    Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
    J Gastroenterol Hepatol. 2020;35:1610-1618.
    PubMed     Abstract available

  51. POUSTCHI H, Majd Jabbari S, Merat S, Sharifi AH, et al
    The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
    J Gastroenterol Hepatol. 2020;35:1590-1594.
    PubMed     Abstract available

    August 2020
  52. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
    Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
    J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
    PubMed     Abstract available

    July 2020
  53. KHAN A, Maheshwari S, Gupta K, Naseem K, et al
    Rate, Reasons, Predictors, and Burden of Readmissions After Transjugular Intrahepatic Portosystemic Shunt Placement.
    J Gastroenterol Hepatol. 2020 Jul 25. doi: 10.1111/jgh.15194.
    PubMed     Abstract available

  54. ZAREBSKA-MICHALUK D, Jaroszewicz J, Buczynska I, Simon K, et al
    Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    J Gastroenterol Hepatol. 2020;35:1238-1246.
    PubMed     Abstract available

  55. FAN J, Wang Q, Luo B, Chen H, et al
    Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
    J Gastroenterol Hepatol. 2020;35:1215-1222.
    PubMed     Abstract available

    June 2020
  56. TAN EZ, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
    Modest alcohol intake is not associated with significant hepatic steatosis nor more severe liver disease among patient with diabetes mellitus.
    J Gastroenterol Hepatol. 2020 Jun 24. doi: 10.1111/jgh.15160.
    PubMed     Abstract available

  57. CAO DB, Wang YS
    Gastrointestinal: Intrahepatic periportal masses with uncommon computed tomography patterns: Hepatic extramedullary hematopoiesis of primary mylofibrosis.
    J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15069.

  58. LEE HW, Ahn SH
    How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:915-916.

  59. SHIN SK, Kim KO, Kim SH, Kwon OS, et al
    Exogenous 8-hydroxydeoxyguanosine ameliorates liver fibrosis through the inhibition of Rac1-NADPH oxidase signaling.
    J Gastroenterol Hepatol. 2020;35:1078-1087.
    PubMed     Abstract available

  60. NGUYEN TH, Wardell R, Chitturi S, Teoh N, et al
    When the liver gets stiff, the tough get moving.
    J Gastroenterol Hepatol. 2020;35:953-959.
    PubMed     Abstract available

  61. CHEN H, He C, Lv Y, Fan J, et al
    Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
    J Gastroenterol Hepatol. 2020;35:1049-1056.
    PubMed     Abstract available

    January 2020
  62. KOGISO T, Sagawa T, Kodama K, Taniai M, et al
    Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14989.
    PubMed     Abstract available

    December 2019
  63. LI Y, Zhang Y, Chen T, Huang Y, et al
    Aldosterone induces activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome.
    J Gastroenterol Hepatol. 2019 Dec 20. doi: 10.1111/jgh.14961.
    PubMed     Abstract available

    November 2019
  64. JOSHITA S, Yamashita Y, Sugiura A, Uehara T, et al
    Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis.
    J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1111/jgh.14929.
    PubMed     Abstract available

  65. FRENCH J, van der Mei I, Simpson S Jr, Ng J, et al
    Increasing Prevalence of Primary Biliary Cholangitis in Victoria, Australia.
    J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14924.
    PubMed     Abstract available

  66. TAKANO K, Saeki C, Oikawa T, Hidaka A, et al
    IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900.
    PubMed     Abstract available

    August 2019
  67. SOBOTKA LA, Risaliti C, Hinton A, Michaels A, et al
    Management of Hepatic Hydrothorax and Effect on Length of Stay, Mortality, Cost, and 30-Day Hospital Readmission.
    J Gastroenterol Hepatol. 2019 Aug 23. doi: 10.1111/jgh.14842.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.